Glenmark Pharmaceuticals

Glenmark Pharmaceuticals (GLENMARK) is a mid-cap Healthcare company valued at ₹62,843 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Glenmark Pharmaceuticals last traded at ₹2,226.7, modestly down 1.06% on the day.

Recent developments

On 2026-10-05, Glenmark Pharmaceuticals expects innovative drugs to drive higher revenue share as the CMD shifts focus beyond generics. On 2026-08-20, the company received USFDA approval for the generic fluticasone propionate nasal spray, which will be distributed in the US. On 2026-07-31, the company reported Q1 results with a sharp rise in profit to ₹483 crore and revenue growth of 23%.

Financial performance

The company's business has improved significantly, with annual revenue rising 27.5% and annual net profit growing 30.1%. The latest quarter saw revenue jump 23.1% and net profit surge 927.3% compared to the same quarter a year earlier, driven by higher margins and strong performance in the generics, Specialty, and OTC segments.

Valuation multiples

The stock trades at 37.9 times earnings, a premium to the Healthcare median of 32.0, 6.49 times book value. It yields 0.2%.

Things to watch

The company's return on equity is 0.0%, which is a concern for profitability relative to shareholder equity. The stock is 9.6% below its 52-week high, indicating a recent pullback from its peak. Domestic institutional holding fell by 0.69 percentage points in the quarter, suggesting some institutional investors may be reducing their positions.

Where it stands

Glenmark Pharmaceuticals has delivered strong growth in both revenue and net profit, with the latest quarter showing an exponential rise in profit. The company's focus on innovative drugs and recent regulatory approvals position it well for future growth. The stock is currently 9.6% below its 52-week high, but the recent positive developments and strong financial performance highlight its potential.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.